For example, a mild virus-activated protein in our network is the serine/threonine kinase MARK2 (Figure 1), which is one of the targets of the drug Fostamatinib in the treatment of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura [85]. This evidence concerns the gene MARK2 and rheumatoid arthritis.